Bone loss after neoadjuvant chemotherapy and total cystectomy for muscle invasive bladder cancer

Bone loss after neoadjuvant chemotherapy and total cystectomy for muscle invasive bladder cancer - Bone loss after neoadjuvant chemotherapy and total cystectomy for muscle invasive bladder cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004087

Enrollment

Registered

2010-08-23

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle invasive bladder cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Aquisition of informed consent Muscle invasive bladder cancer (>=T2) No distant metastasis (M0) Performance status 0-2 of ECOG No liver impairment defined as AST, ALT and T-Bil levels less than 1.5 times as high as institutinal limit, no renal impairment defined as Cr < 2.0 mg/dl, and no hematological abnormalities defined as WBC > 3000000/ml, Hb > 8.0 g/dl, Plts > 100000000/ml

Exclusion criteria

Exclusion criteria: Patients physicians in charge think this study will harm Active double cancer All patients physicians in charge judged to be ineligible

Design outcomes

Primary

Measure	Time frame
Bone mineral density of lumber spine	—

Secondary

Measure	Time frame
Serum BAP and NTx	—

Countries

Japan

Contacts

Public ContactAtsushi Mizokami

Kanazawa University Graduate School of Medical Science Department of Integrative Cancer Therapy and Urology

mizokami@med.kanazawa-u.ac.jp076-265-2393

Outcome results